Suggested remit: To appraise the clinical and cost effectiveness of amivantamab within its marketing authorisation for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 3836

Provisional Schedule

Committee meeting: 1 11 November 2021
Expected publication 02 February 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Consultees

Companies sponsors Janssen-Cilag (amivantamab)
Others Department of Health and Social care
  NHS England
  NHS Herefordshire and Worcestershire CCG
  NHS Hillingdon CCG
  Welsh Government
Patient carer groups Black Health Agency for Equality
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  EGFR Positive UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Interventional Radiology
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated guideline groups National Guideline Alliance
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (docetaxel, carboplatin)
  Boehringer Ingelheim (nintedanib)
  Bristol-Myers Squibb (nivolumab)
  Consilient Health (carboplatin)
  Eli Lilly and Company (pemetrexed)
  Hospira UK (docetaxel, carboplatin)
  MSD (pembrolizumab)
  Roche products (atezolizumab)
  Seacross Pharmaceuticals (docetaxel, pemetrexed)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 March 2021 Invitation to participate
13 January 2021 - 10 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 September 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance